Kenvue

Kimberly-Clark is preparing to divest Kenvue assets to address EU antitrust concerns and aims to secure European Commission approval by the September 29 deadline to avoid a lengthier investigation. The company has already faced similar demands in Australia, where conditional approval required selling Carefree and Stayfree. The acquisition would create a consumer-health and personal-care group with about $32 billion in revenue and $7 billion of adjusted EBITDA; Kimberly-Clark cites roughly $1.9 billion in annual cost synergies and $500 million in revenue synergies but expects to invest $2.5 billion to realize cost savings. The scale of any EU divestitures will determine how much of the deal’s expected economic benefits are preserved, while broader remedies or a prolonged review could reduce acquired earnings and delay synergy realization. » Más en finance.yahoo.com

Kenvue's board of directors approved a quarterly dividend of $0.21 per common share. The payment will be made on October 2, 2026, to shareholders of record at the close of business on September 21, 2026. » Más en de.investing.com

Kenvue has increased the quarterly dividend by 1.2% to $0.21 per common share. The payment will be made on August 26, 2026, to shareholders of record on August 12, 2026. Kenvue operates in the consumer health sector and owns brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena and Tylenol. » Más en de.investing.com